FDA cited EyePoint Pharmaceuticals in Watertown, MA for manufacturing-quality violations affecting its YUTIQ eye implant, including inadequate investigations and process controls.
What happened
FDA inspected EyePoint's drug manufacturing facility in Watertown, MA, from February 6 to 15, 2024. Investigators found inadequate investigations of atypical release rates and failed specification results, weak process control and validation for YUTIQ, missing action levels in manual visual inspection, and release-rate testing not run at the required temperature. FDA called the firm's March 7, 2024 response inadequate.
What FDA found
The firm did not investigate an atypically high release rate in YUTIQ batch 2022-00008, which was released and later had two complaints of failure to achieve the desired therapeutic effect.
21 CFR 211.192Investigations into roof leaks lacked long-term preventive actions, and an out-of-specification investigation remained open past its due date while additional batches were manufactured and released.
21 CFR 211.192The YUTIQ manufacturing process was not scientifically validated; a single-batch blend study had flawed sampling and an unexplained 30% yield, and capping machines were run below required air pressure.
21 CFR 211.100(a) and 211.100(b)Operators did not follow written procedures for handling tools and used an undocumented practice of wiping dispenser tips, and the firm did not generate required statistical process control charts.
21 CFR 211.100(b)Manual visual inspection procedures lacked action levels for significant individual and cumulative defects, and a high rejection rate due to poor polyvinyl alcohol caps was not investigated.
21 CFR 211.110(a)Release-rate testing used centrifuge tubes at a different temperature than the analytical procedure required, which could bias results toward slower release.
21 CFR 211.110(a)
What FDA wants
FDA asks EyePoint to provide comprehensive independent assessments and remediation plans for its investigation, process validation and control, and laboratory and visual inspection systems, along with retrospective reviews and a corrective and preventive action (CAPA) plan. The firm must respond in writing within 15 working days.
Who should pay attention
- brands or application sponsors that rely on EyePoint as a contract manufacturer
- clinicians and patients using YUTIQ intravitreal implants
- quality teams at drug and combination-product manufacturers using manual visual inspection and release-rate testing
This is a summary. Read the original letter on fda.gov.